BiotechTube

Dendritic Cell (DC1) Vaccine + Trastuzumab + Pepinemab + T-Cell therapy

Phase 1Recruiting
0 watching 0 views this week๐Ÿ’ค Quiet
25
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HER2-positive Breast Cancer

Conditions

HER2-positive Breast Cancer

Trial Timeline

May 31, 2022 โ†’ Dec 1, 2026

NCT ID
NCT05378464

About Dendritic Cell (DC1) Vaccine + Trastuzumab + Pepinemab + T-Cell therapy

Dendritic Cell (DC1) Vaccine + Trastuzumab + Pepinemab + T-Cell therapy is a phase 1 stage product being developed by Vaccinex for HER2-positive Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05378464. Target conditions include HER2-positive Breast Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05378464Phase 1Recruiting

Competing Products

20 competing products in HER2-positive Breast Cancer

See all competitors
ProductCompanyStageHype Score
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
CT-0508 + PembrolizumabCarisma TherapeuticsPhase 1
25
CT-0525Carisma TherapeuticsPhase 1
25
TrastuzumabCelltrionPhase 3
77
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
YH32367YuhanPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
77
DS-8201a + T-DM1Daiichi SankyoPhase 3
77
Pertuzumab + Trastuzumab + eribulinEisaiPhase 2
52
Tucatinib 150 MG + Trastuzumab + CapecitabineBioconPhase 2
52
SHR-A1811 Injection + SHR-A1811 Injection ๏ผ› Pertuzumab Injection + Trastuzumab Injection๏ผ›Pertuzumab Injection ๏ผ› Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
77
PyrotinibJiangsu Hengrui MedicinePre-clinical
23
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
77
Pyrotinib + Placebo Oral Tablet + Trastuzumab + DocetaxelJiangsu Hengrui MedicinePhase 3
77
SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ IrinotecanJiangsu Hengrui MedicinePhase 3
77

Other Products from Vaccinex

VX15/2503 + PlaceboPhase 2
44
Pepinemab + PlaceboPhase 1/2
33
Avelumab and PepinemabPhase 1/2
33
VX15/2503 + PlaceboPhase 1
25
VX15/2503Phase 1
25